Molecular Markers/Thyroid Nodules E-Product Theater: Embracing the Prognostic Value of Molecular Markers to Inform Thyroid Nodule Management, Speaker: Erik K. Alexander, MD.
- Categories:
- Product Theater
- Duration:
- 48 Minutes
- Format:
- Audio and Video
Description
A maturing body of evidence suggests molecular markers have prognostic significance in informing tumor phenotype and behavior. In this session Dr. Erik Alexander from Brigham and Women's hospital will review this emerging body of clinical evidence, share his own perspectives, and highlight remaining gaps in using molecular tools to prognosticate tumor behavior and thyroid cancer recurrence risk. This program is made possible with the support of ATA partner Veracyte, Inc.
Credits
Faculty
Erik K. Alexander, MD Related Seminars and Products
Chief, Thyroid Section, Dept of Medicine|Brigham & Women’s Hospital
Professor of Medicine & Associate Dean for UME (BWH)|Harvard Medical School
Dr. Erik K. Alexander is Chief of the Thyroid Section at the Brigham & Women's Hospital, and Professor of Medicine at Harvard Medical School. He is an expert in the field of thyroid nodule evaluation and thyroid cancer care, having published over 200 peer reviewed articles including seminal works in the NEJM, Lancet Endocrinology, JAMA, and the Annals of Internal Medicine. Erik is a member of the 2015 ATA Thyroid Nodule and Cancer clinical guidelines committee, and separately co-chaired the 2017 ATA clinical guidelines on Thyroid illness during Pregnancy. Dr Alexander is a former member of the ATA's Board of Directors. His current work focuses upon novel molecular and genomic understand of disease, and the ability of such efforts to influence prognostic strategy for patients ahead. Separate from his thyroid expertise, Erik is a passionate medical educator and serves as BWH Vice President of Education and HMS Associate Dean for Medical Education.